Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Lazzarin

Showing results (101-110 of 288) with videos related to

Pageof 29
Sort By:
Science Translational Medicine|September 25, 2015
JC polyomavirus mutants escape antibody-mediated neutralizationUpasana Ray, Paola Cinque, Simonetta Gerevini, et al.
The Journal of Antimicrobial Chemotherapy|October 28, 2017
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virusAntonella Castagna, Micol Ferrara, Laura Galli, et al.
AIDS (London, England)|December 20, 2003
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patientsMonica Guffanti, Cleta Raffaella De Pascalis, E Seminari, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 9, 2010
Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trialAlessandro Soria, Anna Danise, Laura Galli, et al.
European Journal of Clinical Pharmacology|July 26, 2005
Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patientsElena Seminari, Monica Guffanti, Paola Villani, et al.
European Journal of Endocrinology|March 29, 2007
Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjectsMonica Guffanti, Andrea Caumo, Laura Galli, et al.
Therapeutics and Clinical Risk Management|January 1, 2014
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital settingGiorgio L Colombo, Antonella Castagna, Sergio Di Matteo, et al.
The New Microbiologica|November 12, 2014
Point-of-care testing for HCV infection: recent advances and implications for alternative screeningMaria Rita Parisi, Laura Soldini, Gianmarino Vidoni, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 11, 2017
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected PatientsMark Nelson, Rafael Rubio, Adriano Lazzarin, et al.
Antiviral Therapy|May 29, 2008
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) studyJudith Currier, Adriano Lazzarin, Louis Sloan, et al.
Pageof 29

Showing results (101-110 of 288) with videos related to

Sort By:
Pageof 29
Science Translational Medicine|September 25, 2015
JC polyomavirus mutants escape antibody-mediated neutralizationUpasana Ray, Paola Cinque, Simonetta Gerevini, et al.
The Journal of Antimicrobial Chemotherapy|October 28, 2017
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virusAntonella Castagna, Micol Ferrara, Laura Galli, et al.
AIDS (London, England)|December 20, 2003
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patientsMonica Guffanti, Cleta Raffaella De Pascalis, E Seminari, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 9, 2010
Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trialAlessandro Soria, Anna Danise, Laura Galli, et al.
European Journal of Clinical Pharmacology|July 26, 2005
Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patientsElena Seminari, Monica Guffanti, Paola Villani, et al.
European Journal of Endocrinology|March 29, 2007
Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjectsMonica Guffanti, Andrea Caumo, Laura Galli, et al.
Therapeutics and Clinical Risk Management|January 1, 2014
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital settingGiorgio L Colombo, Antonella Castagna, Sergio Di Matteo, et al.
The New Microbiologica|November 12, 2014
Point-of-care testing for HCV infection: recent advances and implications for alternative screeningMaria Rita Parisi, Laura Soldini, Gianmarino Vidoni, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 11, 2017
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected PatientsMark Nelson, Rafael Rubio, Adriano Lazzarin, et al.
Antiviral Therapy|May 29, 2008
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) studyJudith Currier, Adriano Lazzarin, Louis Sloan, et al.
Pageof 29